SAMHSA overdose prevention grants did not disappear this year — they got bigger, and at the same time much narrower about what your budget can fund. In July, the Substance Abuse and Mental Health Services Administration pushed a cluster of overdose notices onto Grants.gov with application deadlines days apart, led by an $11 million flagship. The catch is a single line buried in every notice: your narrative and budget cannot support harm reduction. Read the eligibility table and miss that line, and you write a proposal that gets your organization disqualified.

The overdose money moved from a program to a deadline cluster

If you search “SAMHSA overdose prevention grants” expecting one open application, you will misread the landscape. On July 6, SAMHSA announced more than $281 million across 15 grant programs, a large share of it aimed at overdose prevention and response. That announcement is not a single door; it is a schedule. The individual notices of funding opportunity post separately, carry their own numbers, and close within a two-week window at the end of July.

The center of gravity is TI-26-019, Preventing Drug Overdoses: Community Prevention and Response. SAMHSA anticipates $11,050,000 in total funding, 13 awards, and a ceiling of $850,000 per year over a three-year project. The modified notice posted to Grants.gov on July 1, and applications are due July 27. Around it sit a set of sibling programs with the same rhythm: youth-focused overdose prevention, tribal opioid response, emergency-department alternatives to opioids, rural technical assistance, and the largest of them all, medication-assisted treatment. Treat them as one calendar, not one form.

The one line that reshaped every overdose grant

Here is the change that matters more than any dollar figure. As Filter reported when the notices dropped, each 2026 grant notice states that applications must align with SAMHSA strategic priorities and “the application and budget narrative must not support harm reduction.” That is not boilerplate. In April, the agency removed fentanyl test strips from funding eligibility, along with overdose hotlines that support people using drugs alone. Syringe service programs can no longer apply for these grants or even be named in them.

For anyone who has written a federal overdose proposal in the last several years, this inverts a familiar playbook. Test-strip distribution, syringe-access partnerships, and hotline referrals were once standard line items in a “comprehensive” overdose response. Under the current rules, those same items can sink an application. The agency has redefined harm reduction as a model it will not fund, while carving out naloxone access and medications for opioid use disorder as separate, fundable categories. If your program logic model routes through harm reduction, you need to re-anchor it before you write a word of the narrative.

What SAMHSA will actually pay for now

The fundable core of the 2026 overdose portfolio is medication. TI-26-019 exists “to develop and implement a community-wide prevention program to prevent and reduce drug overdose deaths by expanding access to FDA-approved opioid overdose reversal medications” — that is, naloxone and similar reversal drugs. Allowable activities center on purchasing and distributing those medications, training community members and first responders to administer them, medication lock boxes and disposal, and overdose reversal education.

The companion program with the deepest pockets is medication-assisted treatment. Its notice runs to $68.25 million with up to 91 awards near $750,000 each, and it requires recipients to ensure access to methadone and buprenorphine and to pair medication with psychosocial services. A separate First Responders–Comprehensive Addiction and Recovery Act stream carries $34.7 million for naloxone and nalmefene trainings, with faith-based organizations and other “community anchors” explicitly cited as model recipients. The pattern is consistent: money for medications and the systems that deliver them, not for the harm-reduction infrastructure that used to accompany them. When you map your budget, keep every line on the medication-and-training side of that fence. Reviewing the full SAMHSA grants dashboard before you commit tells you which sibling notice fits your services best.

Eligibility is broad, but it is not the gate

TI-26-019 is open to “domestic public and private nonprofit entities, including faith-based organizations.” In practice that reaches community-based organizations, local health departments, community health centers, and treatment providers. That breadth is why so many groups think they qualify — and they do, on paper. The gate is not your tax status; it is whether your project design and budget survive the harm-reduction screen and align with the stated strategic priorities. Organizations that lead with a naloxone-distribution-plus-training model clear it easily. Organizations built around syringe access or test-strip programs do not, no matter how strong their community need data is. A faith-based nonprofit that distributes naloxone and trains volunteers is a textbook fit; a coalition whose signature service is a syringe exchange is not, even if both serve the same neighborhood. Browsing the broader nonprofit grants hub alongside these notices helps mixed-model organizations see which of their programs map to fundable streams and which need a different funder entirely. If you run mixed programming, this is the moment to talk with a grant writer who works in federal health funding about how to scope the application around what is fundable.

Why this window is unusually tight

Two forces compress the timeline. First, the deadline cluster itself: the flagship and several siblings close within days of each other at the end of July, so an organization eyeing more than one notice is juggling near-simultaneous submissions. Second, the policy backdrop is volatile. This funding is the inaugural investment in the administration’s Great American Recovery Initiative, and industry reporting notes the sector is still wary after a chaotic year of behavioral-health funding — a $2 billion cut announced and reversed within a day earlier in 2026, and repeated proposals to restructure the agency. A window that is open and funded today is not guaranteed to reopen on the same terms next cycle.

That argues for treating the current notices as a use-it-or-plan-it moment. If you can realistically assemble a compliant application by July 27, move. If you cannot, do not force a weak submission — instead, build the pipeline now: register early, study the posted notice and application guide, and line up partners so you are drafting from a plan rather than scrambling. The same discipline applies to the block-grant layer, where state-administered funding flows on a different calendar entirely and often becomes the more reliable long-term channel for community providers. Providers that pair a July discretionary application with a mapped state subaward calendar rarely have to bet everything on a single federal window.

A compliance-first checklist before you draft

Because the harm-reduction line is the disqualifier, run your concept through it before investing in a full narrative:

• Scrub the budget. Remove fentanyl test strips, syringe-access line items, and hotline funding. If your model depends on them, redesign the fundable portion around reversal medication and training.
• Anchor on naloxone and MOUD. Make FDA-approved overdose reversal medication distribution, administration training, and, where relevant, medication-assisted treatment the spine of the project.
• Map the right notice. Match your population and services to the correct TI-26 sibling — youth, tribal, rural, emergency department, or the community flagship — rather than defaulting to the biggest number.
• Confirm registrations. Verify your SAM.gov and Grants.gov access is active well before the deadline; a lapsed registration is the most common preventable failure.
• Document need with data. Overdose mortality and surveillance data still strengthen a proposal — just make sure the response you pair with that need is on the fundable side of the line.

Working from a live federal grants database keeps the whole TI-26 family in front of you as notices update, so you are matching to the current version of each opportunity rather than a cached listing on a third-party site.

Frequently Asked Questions

What are SAMHSA overdose prevention grants in 2026?

They are a family of FY2026 federal notices — the “TI-26” series — funding community programs that reduce overdose deaths. The flagship, TI-26-019, provides $11.05 million across 13 awards of up to $850,000 per year. Companion programs cover youth overdose, tribal opioid response, emergency-department alternatives, rural technical assistance, and medication-assisted treatment. Most close in a July deadline cluster.

When is the TI-26-019 application deadline?

The modified notice posted to Grants.gov on July 1, and applications are due July 27. Several sibling programs close within the same two-week window, so if you are pursuing more than one, plan for near-simultaneous submissions rather than a single deadline.

Can my organization still fund harm reduction with these grants?

No. Every 2026 notice states the application and budget narrative must not support harm reduction. SAMHSA removed fentanyl test strips and overdose hotlines from funding eligibility in April, and syringe service programs cannot apply. Naloxone access, reversal training, and medication-assisted treatment are treated as separate, fundable categories.

Who is eligible to apply?

TI-26-019 is open to domestic public and private nonprofit entities, including faith-based organizations — which in practice reaches community-based organizations, local health departments, community health centers, and treatment providers. Eligibility is broad; the real gate is whether your project design and budget clear the harm-reduction screen and align with SAMHSA’s strategic priorities.

How competitive are these awards?

With 13 anticipated awards under the flagship and eligibility open to nonprofits nationwide, they are competitive. Strong applications pair documented local overdose need with a compliant, medication-centered response, credible community partnerships, and a realistic evaluation plan. Programs that misread the harm-reduction language remove themselves from contention before scoring even begins.

Bottom line and next steps

The story of SAMHSA overdose prevention grants this year is not scarcity — it is redefinition. There is more money than last cycle, spread across a coordinated set of July notices, but the agency has drawn a hard line around what that money can buy. The organizations that win will be the ones that internalize the harm-reduction exclusion before drafting, anchor their projects on reversal medication and treatment, and match to the right sibling notice instead of chasing the biggest headline number.

If your deadline is July 27 and your current program model leans on harm reduction, the highest-value move this week is not writing faster — it is re-scoping the fundable core so your budget survives the first screen. When drafting capacity is the constraint against a hard federal deadline, OpenGrants’ grant writing services can carry the narrative and budget build while your team locks in partners and need data, so a compliant application actually reaches the portal on time.